View all discussions
View all audits
please login to access my bpac
Dont have an account? Sign up here
Forgot your login? Reset password
From 1 May, 2018, pregabalin will be available to prescribe, fully subsidised. From 1 June, 2018, prescribing restrictions will be removed from gabapentin
and a new brand will be available, fully subsidised.
There are a multitude of causes of acute pain, however, the approach to management will often be...
Recent amendments have been made to regulations concerning the prescription of some medicinal cannabis products.
The progression of osteoarthritis varies from person to person. Functional decline and worsening of symptoms is not...
Celecoxib is a selective cyclo-oxygenase-2 (COX-2) inhibitor that has been fully subsidised without restriction, since 1 June, 2017.
Methylnaltrexone injections are now subsidised for the treatment of opioid-induced constipation...
A systematic approach is recommended when assessing patients with headache to rule out serious underlying conditions and to ensure...
Selected letters from readers with interactive feedback
Antibiotics Guide 2017 edition
Pharmacological treatment options for patients with COPD
Access your personalised prescribing reports
Discussion points for peer groups or self-reflection of practice
Audits are endorsed by the RNZCGP as a CQI activity for allocation of MOPS credits for General Practitioners
Quizzes are endorsed by RNZCGP for allocation of MOPS credits
our new theme is “Trends in primary care”, covering a range of topics including gout, type 2 diabetes,
immune checkpoint inhibitors and the triple whammy medicine interaction.
our next theme will be a focus on antibiotics
Articles | Mybpac |
About | FAQ | Contact
Made with by the bpacnz team